A liver-targeted LXR inverse agonist has been found to produce rapid, substantial reductions in triglycerides in patients with severe hypertriglyceridemia (SHTG) and metabolic dysfunction-associated steatoticliver disease (MASLD). 

OrsoBio presented the results from its Phase IIa proof-of-concept study of TLC-2716 at the Endocrine Society’s Annual Meeting (ENDO 2026). 

Among patients with baseline triglycerides ≥500 mg/dL — the population at highest risk for acute pancreatitis — both doses (6mg and 12mg) produced consistent placebo-adjusted reductions of approximately 62%.  

TLC-2716 also reduced remnant cholesterol by over 50%, improved liver fat, and was generally well tolerated. 

“These Phase IIa data provide clinical validation of LXR inverse agonism as a differentiated therapeutic strategy for severe metabolic disorders driven by excessive lipogenesis,” said Rob Myers, Chief Medical Officer and Head of Development at OrsoBio. “The significant reductions in triglycerides, remnant cholesterol, and other atherogenic lipids, together with improvements in liver fat, support TLC-2716’s potential across multiple diseases in this space, including SHTG and MASLD.  

“The favourable safety profile and comparable activity across both dose levels suggest meaningful efficacy may be achievable at lower doses in Phase IIb.” 

Liver X receptors (LXRs) are oxysterol-activated nuclear hormone receptors that play a central role in triglyceride and cholesterol homeostasis.  

TLC-2716 is an oral, once-daily, liver-targeted LXR inverse agonist that reduces plasma triglycerides, remnant cholesterol, and liver fat through suppression of hepatic de novo lipogenesis, enhanced clearance of triglyceride-rich lipoproteins, and reduced intestinal lipid absorption. 

Study findings 
  • Triglyceride reduction: TLC-2716 produced rapid, substantial placebo-adjusted reductions in fasting triglycerides at week four of 57% with the 6mg dose and 46% with the 12mg dose in the modified intention-to-treat population. Among patients with baseline triglycerides ≥500 mg/dL, both doses produced consistent placebo-adjusted reductions of approximately 62%. Triglyceride normalisation occurred in 22% of patients receiving 6mg, 30% receiving 12mg, and none receiving placebo.
  • Remnant cholesterol reduction: Placebo-adjusted reductions in remnant cholesterol were 57% with 6mg and 51% with 12mg, representing clinically meaningful reductions in an increasingly recognised driver of residual cardiovascular risk.
  • Broad lipid lowering: Pooled across both TLC-2716 doses, total cholesterol was reduced by 23%, non-HDL cholesterol by 31%, and VLDL cholesterol by 58% versus placebo, with no change in LDL-C or HDL-C.
  • Liver fat reduction: TLC-2716 reduced liver fat by approximately 30% versus placebo, as measured by MRI-PDFF. More than half of treated patients achieved a ≥30% relative reduction in liver fat — a threshold associated with histologic improvement —compared with 30% of placebo-treated patients, consistent with a meaningful treatment effect despite the small sample size.
  • Safety: TLC-2716 was generally well tolerated at both doses, with no Grade ≥3 or serious adverse events reported.